Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 17/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3326304 | 0.88 | RAB9A (0.44) | MIFNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL3327267 | 0.83 | MIF (0.57) | MIFNPC1RAB9ASMN1; SMN2PDE4A | |
| SCHEMBL3325175 | 0.78 | RAB9A (0.34) | MIFNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL29582743 | 0.74 | MIF (0.48) | MIFNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3328596 | 0.73 | MIF (0.53) | MIF | |
| SCHEMBL7470351 | 0.73 | MIF (0.60) | MIFNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL13298912 | 0.72 | MIF (0.59) | MIFNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL6617530 | 0.72 | MIF (0.52) | MIFNPC1RAB9A | |
| SCHEMBL29750189 | 0.71 | MIF (0.51) | MIFNPC1RAB9ASMN1; SMN2HDAC6 | |
| SCHEMBL22870022 | 0.71 | MIF (0.50) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-7396847-B2 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2008-07-08 | — | — | US | disclosed |
| EP-1427711-B1 | OXAZOLIDINONE AND/OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137243-A1 | Oxazolidinone And/Or Isoxazoline As Antibacterial Agents | CYP8B1, HRH2, CYP2W1 | MIF 3446/4885NPC1 3306/4885RAB9A 2624/4885 |
| US-20050107435-A1 | Oxazolidinone and/or isoxazoline as antibacterial agents | CYP8B1, CYP2W1, HRH2 | MIF 3632/4885NPC1 3309/4885RAB9A 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.